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Background	Human	immunodeficiency	virus	(HIV),	as	its	namesake	implies,	is	a	virus	that	ultimately	causes	a	deficient	immune	system	that	can	lead	to	Acquired	Immune	Deficiency	Syndrome	(AIDS).	Since	the	discovery	of	this	cytopathic	virus	in	1983,	there	have	been	many	scientific	advances	in	regards	to	its	identification	and	treatment.	In	1985,	a	diagnostic	serologic	test	was	developed,	and	shortly	after,	in	1987,	antiretroviral	drugs	were	introduced.	Since	these	breakthroughs,	further	improvements	in	diagnosis	and	management	have	been	made	for	individuals	afflicted	with	HIV,	including	the	revolutionary	development	of	combination	antiretroviral	therapy	(cART)	in	1996.	Despite	these	advances,	in	2014,	there	were	an	estimated	1.2	million	people	in	the	United	States	living	with	HIV,	and	an	estimated	44,073	new	HIV	diagnoses.7	Treatment	with	cART	does	not	completely	eradicate	HIV,	and	interruption	of	therapy	leads	to	prompt	increase	in	viral	load,	therefore	lifelong	therapy	is	required	for	viral	suppression.	This	viral	rebound	upon	therapy	cessation	indicates	the	presence	of	an	anatomical	reserve	where	HIV	continues	to	replicate,	better	known	as	latent	reservoirs.	These	reservoirs	are	the	main	hindrance	to	complete	viral	remission,	or	cure.	The	purpose	of	this	paper	is	to	explore	this	problem	and	address	the	clinical	question:	Do	latency-reversing	agents	(LRAs)	eradicate	human	immunodeficiency	virus	(HIV)	in	patients	with	latent	HIV	on	highly	active	antiretroviral	therapy	(HAART)?	This	paper	will	explore	relevant	epidemiology,	pathophysiology,	and	innovative	research	on	this	topic	and	then	address	the	question	of	LRAs’	role	in	the	eradication	of	HIV.3		
Epidemiology	The	major	modes	of	acquiring	HIV	infection	include	sexual	transmission,	parenteral	transmission,	and	perinatal	transmission.	7	HIV	transmission	occurs	through	certain	body	fluids	from	an	infected	individual,	such	as	blood,	semen,	pre-seminal	fluid,	rectal	fluid,	vaginal	fluid,	and	breast	milk.5	These	body	fluids	must	be	exposed	to	a	mucous	membrane	or	injured	tissue,	or	be	directly	injected	into	the	bloodstream	for	HIV	acquisition.	5	The	relative	importance	of	these	various	modes	of	HIV	transmission	vary	geographically,	and	are	outlined	below.		Sexual	Transmission	Worldwide,	more	than	80%	of	HIV	infections	occur	via	heterosexual	transmission,	and	over	50%	of	all	HIV-infected	individuals	are	women.7	This	data	reflects	HIV	infection	in	sub-Saharan	Africa,	which	contributes	to	the	majority	of	the	world’s	infected	population.7	In	other	parts	of	the	world,	more	men	than	women	are	infected	with	HIV,	which	sheds	light	on	the	men	who	have	sex	with	men	(MSM)	population.7	The	MSM	population	is	19	times	more	likely	than	the	general	population	to	acquire	HIV.7	In	2013,	MSM	transmission	comprised	68%	of	new	HIV	diagnoses	in	the	United	States.7		 Parenteral	Transmission		 Injection	drug	use	accounts	for	approximately	30%	of	new	HIV	diagnoses,	outside	of	sub-Saharan	Africa.7	In	2014,	injection	drug	use	made	up	5%	of	new	HIV	infections	in	the	United	States.5	
		
	 Perinatal	Transmission		 Children	are	susceptible	to	HIV	transmission	in	utero,	at	birth,	or	through	breastmilk.7	Annually,	greater	than	2	million	infants	are	born	to	HIV	infected	mothers.7		Since	this	paper	will	focus	on	research	conducted	in	the	United	States,	the	following	epidemiology	will	reflect	statistics	within	this	geographical	location.	In	2014,	the	number	of	deaths	of	individuals	with	an	HIV	diagnosis	and	AIDS,	was	12,333.4	Cumulatively,	the	estimated	number	of	deaths	of	individuals	with	HIV	and	AIDS	through	2014,	was	678,509,	by	any	cause.5	AIDS	is	the	fourth	leading	cause	of	death	worldwide.7	This	fact,	along	with	the	alarming	statistics	above,	leads	to	discussion	of	the	pathophysiology	of	the	virus,	and	why	HIV	infection	has	sustained.	
Pathophysiology	HIV	infects	and	subsequently	undergoes	viral	replication	within	T-lymphocytes	expressing	CD4	antigen.	These	CD4	positive	cells	are	a	critical	component	of	normal	cell-mediated	immunity.	After	HIV	acquisition,	the	individual,	or	host,	is	predisposed	to	various	opportunistic	infections,	such	as	Pneumocystis	
jiroveci	(carinii)	pneumonia,	and	neoplasms,	such	as	lymphoma	and	Kaposi’s	sarcoma.	6,8	HIV	also	infects	brain	monocytes	and	macrophages,	producing	significant	central	nervous	system	symptoms	via	multinucleated	giant	cells.	HIV	may	disrupt	blood	monocyte,	tissue	macrophage,	and	B-lymphocyte	(humoral	immunity)	function,	predisposing	host	to	infection	with	encapsulated	bacteria.	The	chief	
immune	response	to	HIV	infections	involves	cytotoxic	CD8	positive	lymphocytes,	which	response	to	initial	infection,	and	regulate	it	for	many	years.	Mutant	HIV	strains	are	controlled	by	proliferation	of	new	clones	of	cytotoxic	T	cells.	These	cells	will	begin	to	fail	when	the	majority	of	CD4	T	cells	have	died,	thus	diminishing	the	supply	of	lymphokines	essential	to	activate	the	cytotoxic	T	cells.	This	failure	inevitably	leads	to	AIDS.6	Three	mechanisms	provide	explanation	why	HIV	infection	persists	despite	the	immune	system:	(1)	integration	of	viral	DNA	into	host	cell	DNA,	(2)	a	high	mutation	rates	(3)	the	production	of	specific	proteins	that	downregulate	class	I	MHC	proteins	needed	for	cytotoxic	T	cells	to	recognize	and	kill	cells	infected	with	HIV.6	Clinically,	HIV	infection	can	be	divided	into	three	stages,	each	of	which	is	outlined	below.		Early,	acute	stage	Acute	HIV	begins	one	to	four	weeks	after	infection,	when	patients	may	experience	a	symptomatic	mononucleosis-like	syndrome	of	lethargy,	fever,	sore	throat,	and	generalized	lymphadenopathy.	A	maculopapular	rash	of	the	trunk	and	extremities	may	also	be	seen.	At	a	cellular	level,	acute	HIV	is	accompanied	by	an	increase	in	viral	replication,	and	a	decrease	in	CD4	cell	count.	Infection	is	established	by	high-level	viremia,	in	the	absence	of	HIV	antibody.	Once	the	acute	stage	resolves	in	about	two	weeks,	HIV	RNA	decreases	slightly,	and	CD8	positive	T	cells	directed	against	HIV	increase.6		Infected	individuals	undergo	seroconversion	three	to	four	weeks	after	infection,	or	have	a	positive	HIV	antibody	test.	This	period	of	time	where	HIV	
antibody	is	undetectable,	may	lead	to	false	negative	results	when	attempting	to	confirm	HIV	infection.	These	patients	are	still	able	to	transmit	infection,	and	if	diagnostic	suspicion	is	high,	serum	should	be	sent	for	HIV	RNA	PCR.6	Approximately	87%	of	individuals	who	become	seropositive	during	acute	infection,	are	symptomatic,	and	about	13%	will	experience	an	asymptomatic	initial	infection.6	Asymptomatic	HIV	is	accompanied	by	a	gradual	decrease	in	CD4	cell	counts,	and	viremia	levels	out	to	a	“set	point”,	or	a	relatively	stable	viral	load.	A	viral	set	point,	typically	established	by	approximately	6	months	of	infection,	can	vary	from	person	to	person,	and	signifies	the	amount	of	virus	produced,	which	remains	stable	for	years.	The	set	point	can	be	an	important	piece	of	information	when	evaluating	patients	with	HIV.	After	initial	infection,	the	higher	the	set	point,	the	more	likely	the	individual	will	progress	to	symptomatic	AIDS.6	Chronic	HIV	infection	without	AIDS	This	stage	is	characterized	by	viral	load	stability,	and	gradual	decline	in	CD4	cell	count.	In	untreated	patients,	this	latent	period	typically	lasts	8-10	years.3	The	majority	of	patients	within	in	this	stage	of	infection	are	asymptomatic,	although	many	patients	will	present	with	generalized	lymphadenopathy	on	physical	exam.3	As	the	CD4	cell	count	decreases,	a	syndrome	termed	as	AIDS-related	complex	(ARC)	can	occur	during	this	stage.	This	syndrome	consists	of	persistent	fevers,	fatigue,	weight	loss,	and	lymphadenopathy.	This	syndrome	is	important	to	recognize,	because	ARC	often	progresses	to	AIDS.6	This	stage	is	of	particular	interest	in	untreated	patients	because	cell	death	and	replacement	are	in	close	balance.	Although	HIV	is	replicating	at	a	high	rate,	and	
CD4	cells	are	being	destroyed,	the	CD4	cell	count	decline	is	slow,	and	the	viral	load	is	relatively	stable.	This	is	because	a	large	amount	of	HIV	production	is	occurring	within	lymph	node	cells,	but	remains	sequestered	here,	thus	the	lymphoid	tissue	is	a	major	reservoir	for	HIV.	As	the	disease	progresses,	the	lymph	node	tissue	is	disturbed,	and	increased	amounts	of	HIV	is	peripherally	released	into	the	bloodstream.3,6	AIDS	and	advanced	HIV	infection	Chronic	HIV	infection	without	treatment	transitions	to	AIDS	when	the	CD4	cell	count	is	below	200	cells/microL,	and/or	the	presence	of	opportunistic	infections.	These	opportunistic	infections	are	often	referred	to	as	AIDS	defining	conditions,	and	include	Pneumocystis	jiroveci	pneumonia,	tuberculosis,	cryptococcal	meningitis,	candidal	esophagitis,	central	nervous	system	toxoplasmosis,	and	non-Hodgkin’s	lymphoma.	Most	AIDS-related	deaths	occur	when	the	CD4	cell	count	falls	below	50	cells/microL,	and	deaths	are	usually	related	to	late	stage	opportunistic	infections,	such	as	disseminated	Mycobacterium	avium	complex	(MAC),	or	cytomegalovirus	disease.3,6,8	This	complex	pathophysiology	leads	to	the	discussion	of	why	HIV	eradication	is	difficult,	despite	medical,	and	pharmaceutical	advances.	One	barrier	to	complete	HIV	suppression	is	latently	infected	reservoirs.	Latently	infected	reservoirs	are	defined	as	cells	that	contain	the	integrated	HIV	genome,	are	transcriptionally	silent,	but	able	to	virally	replicate.	The	main	cellular	reservoirs	of	HIV	are	resting	CD4	positive	T-cells.	Other	types	of	reservoirs	include	peripheral	blood	monocytes,	dendritic	cells,	and	macrophages,	including	the	microglial	cells	with	are	central	
nervous	system	macrophages.	The	reason	why	these	reservoirs	serve	as	an	obstacle	to	HIV	eradication	is	their	location,	which	is	referred	to	as	“sanctuaries”.	These	sanctuaries,	including	the	male	genital	tract,	adipose	tissue,	lymph	nodes,	and	the	central	nervous	system,	are	areas	of	poor	cART	penetration,	and	ultimately	efficacy.	Various	reservoirs	other	than	CD4	T	cells,	such	as	macrophages,	exist	within	the	immune	privileged	area	of	the	brain.	The	central	nervous	system	is	considered	a	sanctuary	for	many	reasons.	The	blood	brain	barrier	and	choroid	plexus	serve	as	obstacles	for	drug	penetration	of	currently	used	cART.	Also,	the	target	reservoirs	of	the	brain	are	astrocytes	and	microglial	cells,	which	many	existing	cART	do	not	target.10	Innovative	research	on	how	to,	essentially	“shock”,	latent	HIV	out	of	these	reservoirs,	led	to	latency	reversing	agents	(LRAs).	Originally	histone	deacetylase	(HDAC)	inhibitors	were	developed	as	oncologic	agents,	due	to	HDACs	importance	in	transcriptional	regulation,	and	cell	death.	Research	has	led	to	use	of	HDAC	inhibitors	as	LRAs,	by	reactivating	HIV	secondary	to	transcriptional	induction,	and	is	the	main	LRA	examined	in	this	paper.	Other	LRAs	include	histone	methyltransferase	inhibitors,	disulfiram,	protein	kinase	C	agonists,	proteasome	inhibitors,	and	Toll-like	receptor	7	agonists.10	
Methods		 	Search	strategy	was	primarily	conducted	electronically.	The	databases	PubMed	and	Google	Scholar	were	searched	from	2007-2017	for	articles	in	English.	The	search	terms	that	were	utilized	in	these	databases	were	as	follows:	eradication,	
HIV,	latency,	reservoir,	cure,	remission,	shock,	kill,	reversal,	vorinostat,	and	latency	reversing	agent.		Exclusion	criteria	applied	to	the	search	results	included	studies	conducted	outside	the	United	States.	Also,	studies	that	evaluated	subjects	that	were	not	virally	suppressed,	or	were	treatment	naïve,	were	excluded.	Inclusion	criteria	were	set	for	abstracts	of	populations	that	were	HIV	infected,	aviremic,	and	cART	treated.	Further	inclusion	criteria	included	trials	observing	ex	vivo	response	to	LRAs.	A	bias	evaluation	was	performed	for	all	trials	utilizing	the	Cochrane	Risk	of	Bias	Tool.	Selection	bias	for	all	trials	was	low,	since	all	patients	and	samples	were	de-identified.	No	bias	was	present	in	selection	of	participants	of	study,	although	patients	recruited	for	all	trials	had	to	be	HIV-infected,	and	receiving	stable	standard-of-care	cART,	with	plasma	HIV	RNA	levels	below	50	copies/mL.	Although	participants	and	trial	personnel	were	aware	of	assigned	intervention	for	all	trials,	there	were	no	deviations	from	intended	interventions,	producing	a	low	performance	and	detection	bias.	Attrition	bias	was	also	low	for	all	trials,	as	patients	and	their	samples	were	monitored	and	followed	closely,	and	only	excluded	from	progressing	in	the	trials	if	a	statistically	significant	response	was	not	produced.		Additional	epidemiological	and	pathophysiological	data	was	acquired	through	search	and	review	of	clinical	decision	resource	UpToDate.		
Results		 The	data	acquisition	methods	described	above	yielded	a	total	of	10	abstracts,	and	3	were	included	for	discussion	in	this	review.		
Archin,	et.	al’s	study,	“Interval	dosing	with	the	HDAC	inhibitor	vorinostat	effectively	reverses	HIV	latency”,	is	a	phase	I-II	single-center	study	that	will	demonstrate	how	LRAs	operate,	ex	vivo,	and	in	vivo.	This	study	used	vorinostat,	an	HDAC	inhibitor,	as	its	LRA,	along	with	the	principle	that	repeated	disturbance	of	latency	is	required	for	successful	total	HIV	RNA	suppression.	The	study	evaluated	effective	LRA	dosing	regimens	that	would	cause	repeated	HIV	RNA	expression,	and	therefore	allow	treatment	of	persistent	HIV	infection.2		 The	study	enrolled	16	HIV	infected,	aviremic,	cART	treated	subjects	to	determine	the	optimal	in	vivo	vorinostat	dosing	schedule	required	for	effective	successive	disruption	of	CD4	positive	T	cells.	The	vorinostat	dose	used,	400mg,	was	derived	from	oncology	studies,	which	demonstrated	maximal	efficacy	with	minimal	drug	toxicities,	including	transient	thrombocytopenia,	and	gastrointestinal	symptoms.	Leukapheresis	evaluation	was	performed	on	each	subject’s	sample,	drawing	out	CD4	T	cells,	which	were	then	tested	with	a	dose	of	vorinostat.	HIV	RNA	production	was	measured	to	see	if	the	subject’s	cells	reacted	to	the	LRA,	and	only	those	that	did	respond,	were	included	in	the	next	leg	of	the	study.	Further	ex	vivo	analysis	was	conducted,	resulting	in	data	suggesting	that	daily	LRA	exposure	blunts	the	viral	response,	and	that	paired	doses	at	either	48	or	72	hours	should	be	administered	for	maximum	latency	reversal.2		 Only	participants	with	a	measurable	increase	in	HIV	RNA	after	ex	vivo	exposure	to	vorinostat	–	12	out	of	16	-	were	administered	a	single	dose	of	in	vivo	LRA.		Out	of	the	12	participants	that	received	an	in	vivo	dose	of	vorinostat,	only	7	had	a	significant	increase	in	HIV	RNA	isolated	from	CD4	T	cells,	with	no	increase	in	
the	remaining	4	participants.	From	the	ex	vivo	dosing	data,	the	first	participant	out	of	the	7,	received	a	paired	dose	at	a	48	hour	interval.	This	did	not	result	in	HIV	RNA	increase	of	statistical	significance.	The	participant	subsequently	received	a	paired	dose	of	vorinostat	at	the	72-hour	interval,	which	resulted	in	a	significant	increase	of	HIV	RNA	produced	by	CD4	T	cells.2		 Due	to	the	increased	efficacy	of	the	72-hour	interval	dosing	in	vivo	in	the	previous	participant,	and	toxicity	concerns	related	to	alternate	day	dosing	of	vorinostat,	the	remaining	6	participants	received	paired	dosing	at	the	72-hour	interval.	A	significant	response	was	measured	in	5	out	of	6	participants.	Ultimately	3	out	of	these	5	participants	chose	to	receive	10	consecutive	doses	of	vorinostat	at	72	hour	intervals,	to	evaluate	if	this	pulsatile,	and	serial,	LRA	exposure	would	activate	persistent	HIV	infection.	Out	of	these	3	participants,	2	showed	a	statistically	significant	prolonged	elevation	of	HIV	RNA.	See	Figure	1	for	summarized	outline	of	how	subjects	progressed	through	study.2										
		
Figure	1	Throughout	the	study,	latent	HIV	within	the	CD4	T	cell	reservoir	was	measured	using	a	quantitative	viral	outgrowth	assay	(QVOA)	at	baseline,	and	following	paired,	and	consecutive	vorinostat	dosing.	From	this	data,	no	significant	
16	HIV	infected,	aviremic,	cART treated	subjects	enrolled
12	out	of	16	subjects	with	measurable	increase	in	HIV	RNA	after	ex	vivo	exposure	to	vorinostat
7	out	of	12	subjects	with	significant	increase	in	HIV	RNA	after	en	vivo	dose	of	vorinostat
1	out	of	7	subjects	received	paired	vorinostat dose	at	48	hour	interval,	with	no	statistically	significant	increase	in	HIV	RNA.	Subsequently	received	additional	paired	dose	at	72	hour	interval,	with	increase	in	HIV	RNA
Remaining	6	subjects	received	paired	dosing	at	72	hour	interval
Significant	response	measured	in	5	out	of	6	subjects
3	out	of	5	subjects	chose	to	receive	10	consecutive	doses	of	vorinostat at	72	hour	intervals
2	out	of	3	subjects	demonstrated	a	statistically	prolonged	elevation	of	HIV	RNA
reduction	in	latent	virus	recovered	with	QVOA	was	observed,	along	with	no	change	in	HIV	RNA	after	in	vivo	vorinostat.	Therefore	the	study	found	that	multiple	doses	of	vorinostat	minimally	impacts	reservoir	cells	in	vivo.2		 The	use	of	multiple	LRAs,	with	different	mechanisms	of	action,	is	examined	in	Albert,	Ramani	et.	al’s	study	“Combinations	of	isoform-target	histone	deacetylase	inhibitors	and	bryostatin	analogues	display	remarkable	potency	to	active	latent	HIV	without	global	T-cell	activation.”	A	critical	deficiency	of	HDAC	inhibitors	is	lack	of	specificity,	resulting	in	pan-inhibition	of	HDAC	classes,	and	subsequently	unwanted	side	effects.	Side	effects	include	fatigue,	nausea,	diarrhea,	prolonged	QT	interval,	thrombocytopenia,	lymphopenia,	and	neutropenia.	This	study	compared	an	isoform-targeted	compound	of	an	HDAC	inhibitor,	largazole,	with	other	HDAC	inhibitors,	including	vorinostat.	The	isoform	compound	is	described	to	be	more	specific	for	HIV	latency	reversal,	than	its	other	HDAC	inhibitor	counterparts,	producing	decreased	side	effects.	Comparison	was	conducted	ex	vivo	on	T-cell	lines,	and	using	fluorescence	activating	sorting	(FACS)	analysis.	In	short,	stronger	HIV	reactivation	–	the	desired	result	–	will	generate	a	more	intense	fluorescent	signal.	Three	various	isoforms	of	largazole	demonstrated	superior	latent	HIV	reactivation,	compared	to	15	other	HDAC	inhibitors.1		 Largazole	was	then	combined	with	a	different	LRA,	bryolog,	to	evaluate	potential	synergistic	effect.	Bryolog	was	also	combined	with	the	other	15	HDAC	inhibitors	for	comparison.	This	was	conducted	ex	vivo,	on	T-cell	lines.	It	was	found	that	the	largazole	combinations	with	bryolog	demonstrated	unprecedented	synergistic	potency	has	HIV	LRAs.		This	combination	was	further	evaluated	for	
toxicity	related	to	cytokine	release,	and	it	was	found	that	this	synergistic	combination	avoided	global	T-cell	activation.	This	was	done	by	incubating	T	cells	with	the	LRA	combination,	and	using	ELISA	to	evaluate	cytokine	release.1	These	study	findings	lead	to	analysis	of	“On	the	Way	to	Find	a	Cure:	Purging	Latent	HIV-1	Reservoirs”,	by	Schwartz	et.	al,	to	demonstrate	limitations	of	LRAs	used	as	the	only	mechanism	in	attempt	to	clear	persistent	HIV	infection.	This	study	describes	how	many	of	the	viral	reservoirs	are	located	in	sanctuaries,	or	“immune	privileged”	areas	of	poor	cART	efficacy,	and	drug	penetration.	As	described	previously,	these	sanctuaries	include	the	male	genital	tract,	adipose	tissue,	lymph	nodes,	and	the	central	nervous	system.	This	article	is	highlighted	here	in	order	to	demonstrate	the	need	to	consider	the	type	and	dispersal	of	latently	infected	cells,	in	order	to	most	effectively	reduce	the	HIV	reservoirs.	For	example,	ex	vivo	analysis	of	CD4	T	cells	in	response	to	LRAs,	may	provide	insight	into	if	latent	virus	exists	and	is	able	to	reactivate,	but	does	not	shed	light	on	if	these	reservoirs	are	located	in	sanctuaries.10		 Overall,	the	results	from	these	studies	demonstrate	that	use	of	a	single	LRA	will	not	achieve	complete	latency	reversal.	A	synergistic	approach	using	various	mechanisms	of	action	that	target	HIV	reservoirs	is	required.	These	results	prove	that	combination	LRAs	over	multiple	courses	is	necessary	for	persistent	HIV	infection.	Additional	in	vivo	research	needs	to	be	explored	from	this	mainly	ex	vivo	analysis,	to	further	evaluate	if	combination	LRAs	will	penetrate	sanctuaries,	as	well	as,	produce	minimal	adverse	effects.			
Discussion	From	this	analysis,	it	is	evident	that	a	multifaceted	strategy	must	be	utilized	in	order	for	complete	latent	HIV	reactivation,	and	elimination	in	poor	drug	delivery	sites.		 In	regards	to	the	study	conducted	by	Archin	et.	al,	the	number	of	participants	evaluated	was	very	limited,	but	the	results	may	be	useful	in	future	guidance	of	vorinostat	dosing,	and	study	design,	since	the	idea	of	LRAs	is	relatively	new.	The	results	of	this	study,	that	no	significant	depletion	of	viral	reservoir	was	observed,	could	be	due	to	many	factors.	One	factor	is	that	the	number	of	LRA	doses	the	participants	received	may	not	be	enough	for	measurable	viral	reservoir	decline.	Another	factor,	which	was	discussed	in	the	second	article,	is	that	latently	infected	reservoirs	in	sanctuaries,	are	most	likely	inadequately	able	to	clear	virus	due	to	poor	cART	penetration,	and/or	immune	cell	access.		Another	limitation	of	Archin	et.	al	discussed,	is	that	the	one	participant	out	of	the	3	that	received	10	consecutive	vorinostat	doses,	that	did	not	demonstrate	a	statistically	significant	increase	of	HIV	RNA	from	its	CD4	T	cells,	could	be	due	to	LRA	non-adherence.	This	participant	reported	difficulty	with	compliance	to	72	hour	interval	dosing,	which	may	have	contributed	to	lack	of	significant	response.	How	this	altered	dosing	regimen	affected	viral	response	cannot	be	completely	evaluated.		Due	to	the	high	mutation	rate	of	HIV,	cell	mediated	immune	responses	often	fail,	leading	to	another	difficulty	for	complete	viral	eradication.	This	along	with	the	presence	of	sanctuaries,	necessitate	combination	therapies	that	enhance	both	cell-mediated	and	humoral	immunity	are	necessary	for	effective	reactivation	of	latent	
HIV,	along	with	therapies	that	are	able	to	clear	this	persistent	infection.	In	regards	to	humoral	immunity,	extensive	research	in	vaccine	development	has	been	conducted	since	the	discovery	of	HIV,	but	all	clinical	trials	have	failed	to	date.	Innovative	research	on	broadly	neutralizing	antibodies	proves	promising.	These	antibodies	were	discovered	from	HIV	infected	individuals,	and	can	neutralize	many	HIV	strain	variants.	These	antibodies	can	be	detected	in	approximately	25%	of	individuals	with	treatment	naïve	HIV	infection,	which	suggests	a	host	immune	response	to	viral	replication,	and	production	of	numerous	viral	variants.	Cell-mediated	immune	responses	targeting	reduced	cytotoxic	T	cell	variants,	and	improved	CD8	positive	or	natural	killer	cell	responses,	have	to	be	also	considered	in	a	the	manifold	approach	of	HIV	eradication.10	Schwartz	et.al,	goes	on	to	further	explain	how	LRAs	are	unable	to	significantly	reduce	the	size	of	HIV	reservoirs,	due	to	the	fact	that	despite	increased	latent	HIV	expression	due	to	LRAs,	this	does	not	ultimately	lead	to	the	death	of	these	infected	cells.	HIV	also	impairs	the	cytotoxic	activity	of	CD8	positive	T	cells,	which	is	not	remedied	by	cART.		This	leads	to	discussion	of	a	“shock	and	kill”	strategy,	where	the	LRA	“shocks”	the	virus	in	reservoirs,	and	the	patient’s	immune	system	needs	to	somehow	be	boosted	to	“kill”	the	remaining	virus.	The	“kill”	is	employed	through	both	cell-mediated,	and	humoral	immunity,	which	should	be	both	augmented.	This	complicated	strategy	leads	to	further	discussion	of	use	of	LRAs	in	the	setting	of	persistent	HIV	infection.10	Overall,	further	research	on	how	to	steer	immune	response	to	sanctuaries,	or	immune	privileged	areas	where	latently	infected	reservoirs	are	located,	need	to	be	
explored.	The	complex	molecular	mechanisms	of	dormant	HIV	require	further	research	in	order	to	create	strategies	to	target	sanctuaries,	and	reservoirs	other	than	CD4	T	cells.	Boosting	humoral	immune	response	through	further	identification	and	classification	of	broadly	neutralizing	antibodies,	and	improving	virus	specific	cytotoxic	T	cell	mediated	responses,	are	necessary	for	the	multi-dimensional	attack	on	HIV.	Furthermore,	use	of	one	LRA	which	targets	a	single	mechanism	involved	in	latency,	is	unlikely	to	be	effective	in	vivo.																			
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